1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025

  • February 2017
  • 403 pages
  • GlobalData
Report ID: 2788799

Summary

Table of Contents

Search Inside


PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025

Summary
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over six million individuals in the 8MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, and Australia) and this prevalence is expected to grow to just shy of 7 million individuals by 2025. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease.

The RA market in the 8MM is expected to grow at a Compound Annual Growth Rate (CAGR) of 3.9% during the forecast period, from 2015 sales of $19.5 billion to sales of $28.5 billion in 2025.

The major drivers of growth in the global RA market during the forecast period are -
- An increase in the prevalent cases of RA in all the markets, in part, due to an aging population.
- The launch and continued uptake of biosimilars for all established biologics on the RA market (infliximab, etanercept, adalimumab, golimumab, certolizumab pegol, tocilizumab, abatacept, and rituximab) in all the markets covered in the report, which is expected to lead to an increase in patient volume by making treatments more accessible.
- The early diagnosis and treatment of patients with RA to limit disease progression.

The RA market is dominated by Big Pharma, and most of the compounds in late-stage development are backed by a major pharmaceutical company. The major players in the RA market have extensive portfolios, and may enter into Phase I buyouts and partnerships at very early stages. It is especially common for these companies to form an early partnership for development in the Japanese market.

Biosimilars for all established biologics are expected to launch in all 8MM by 2025, with the exception of etanercept in the US and certolizumab in Japan. Overall, the market share of biosimilars will account for 23% of the 8MM RA market in 2025. It is this potential segment of the RA market that Big Pharma companies such as Pfizer and Amgen have realized, and as such are pursuing their own biosimilar development programs.

The report "PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2025" provides an overview of rheumatoid arthritis (RA), including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.

In depth, this report provides the following analysis -
- Provides comprehensive data split across different phases and emerging trends, specifically JAK inhibitors (such as Eli Lilly/Incyte’s Olumiant (baricitinib), novel biologics (such as AstraZeneca-MedImmune’s mavrilimumab), and biosimilars (such as Celltrion/Hospira/Pfizer’s Inflectra/Remsima, Samsung Bioepis/Biogen/Merck’s Flixabi and Benepali, Sandoz’s Erelzi, and Amgen’s Amjevita).
- Provides annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Analysis of strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the RA biologics and biosimilars markets.
- Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges.

Companies mentioned in this report: AbbVie, Pfizer, Amgen, Johnson & Johnson, Eli Lilly, Bristol-Myers Squibb, UCB, Roche, GlaxoSmithKline, Novartis, Sanofi, AstraZeneca-MedImmune, Astellas, Daiichi Sankyo, Samsung Bioepis, Sandoz.

Scope
- Overview of rheumatoid arthritis (RA), including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.
- Annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the RA biologics and biosimilars markets.
- Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically JAK inhibitors (such as Eli Lilly/Incyte’s Olumiant (baricitinib), novel biologics (such as AstraZeneca-MedImmune’s mavrilimumab), and biosimilars (such as Celltrion/Hospira/Pfizer’s Inflectra/Remsima, Samsung Bioepis/Biogen/Merck’s Flixabi and Benepali, Sandoz’s Erelzi, and Amgen’s Amjevita).
- Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the RA market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the eight major RA markets from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Ulcerative Colitis Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Ulcerative colitis is a chronic inflammatory bowel disease that is characterized by inappropriate diffuse inflammation of the rectal and colonic mucosa, which occurs in the innermost laye ...

Crohn’s Disease Market and Forecast Analysis

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Crohn’s disease involves inflammation of the gastrointestinal (GI) tract and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of ...

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • February 2017
  • by GlobalData

OpportunityAnalyzer: Immune Thrombocytopenia (ITP) - Opportunity Analysis and Forecasts to 2025 Summary Immune Thrombocytopenia (ITP) is an autoimmune-related bleeding disorder characterized by a low platelet ...

Hnscc: Kol Insight - 2017

March 2017 $ 8355

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.